Cytokinetics Stock Price, News & Analysis (NASDAQ:CYTK)

$10.05 0.50 (5.24 %)
(As of 01/23/2018 04:00 PM ET)
Previous Close$10.05
Today's Range$9.60 - $10.10
52-Week Range$7.00 - $17.20
Volume376,155 shs
Average Volume330,227 shs
Market Capitalization$529.42 million
P/E Ratio-6.05
Dividend YieldN/A
Beta1.61

About Cytokinetics (NASDAQ:CYTK)

Cytokinetics logoCytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CYTK
CUSIPN/A
Phone+1-650-6243000

Debt

Debt-to-Equity Ratio0.14%
Current Ratio7.60%
Quick Ratio7.60%

Price-To-Earnings

Trailing P/E Ratio-6.05421686746988
Forward P/E Ratio-4.19
P/E GrowthN/A

Sales & Book Value

Annual Sales$106.41 million
Price / Sales5.09
Cash Flow$0.44 per share
Price / Cash22.68
Book Value$2.32 per share
Price / Book4.33

Profitability

Trailing EPS($1.66)
Net Income$16.45 million
Net Margins-172.27%
Return on Equity-62.64%
Return on Assets-29.08%

Miscellaneous

Employees127
Outstanding Shares53,880,000

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) issued its quarterly earnings data on Thursday, October, 26th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.64) by $0.04. The biopharmaceutical company had revenue of $6.18 million for the quarter, compared to the consensus estimate of $5.35 million. Cytokinetics had a negative return on equity of 62.64% and a negative net margin of 172.27%. View Cytokinetics' Earnings History.

When will Cytokinetics make its next earnings announcement?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Cytokinetics.

Where is Cytokinetics' stock going? Where will Cytokinetics' stock price be in 2018?

10 Wall Street analysts have issued 1-year price objectives for Cytokinetics' stock. Their predictions range from $10.00 to $25.00. On average, they expect Cytokinetics' share price to reach $18.20 in the next twelve months. View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:

  • 1. Cantor Fitzgerald analysts commented, "CYTK is on track for the readout of tirasemtiv in the pivotal VITALITY-ALS study at the International Symposium on ALS/MND (December 8-10)." (9/26/2017)
  • 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
  • 3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)
  • 4. Rodman & Renshaw analysts commented, "Our price target is based on our clinical net present value (NPV) model, which is currently driven by omecamtiv mecarbil ($19.77/share) and modest contributions from tirasemtiv ($4.26/share) and CK-107 ($1.05/share). We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (3/23/2017)
  • 5. HC Wainwright analysts commented, "We have adjusted our 2017 estimates downward accordingly. The company had a net loss of $4.3M in 4Q16, or ($0.81) per share based on shares adjusted for the 1-for-10 reverse split effective on February 27. 2016. The loss was lower than our estimate of $4.9M due to improved expense management. For the fiscal year 2016, TearLab had $28M in revenue, representing 11% growth over that of 2015, and $19.9M in net loss. In our view, the softened growth rate in the Flex program and in international markets could continue in 2017. Therefore, we currently project a conservative low single-digit growth in revenue in 2017. Our valuation of the company has decreased from $140M to $105M. Excluding debt, our estimated market value of the firm is $79M. Assuming 6.5M shares outstanding at the end of 2017, we project a 12-month price target of $12 per share. Our previous price target was $2 before the reverse split. Importantly, TearLab has begun a process to explore strategic alternatives, which does not preclude a sale of the company." (3/13/2017)

Who are some of Cytokinetics' key competitors?

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:

  • Leonard Patrick Gage Ph.D., Independent Chairman of the Board (Age 74)
  • Robert I. Blum, President, Chief Executive Officer, Director (Age 53)
  • Ching Jaw, Chief Financial Officer, Senior Vice President (Age 54)
  • Sharon A. Barbari, Executive Vice President - Finance (Age 62)
  • Fady I. Malik M.D. Ph.D., Executive Vice President - Research and Development (Age 52)
  • Peter S. Roddy, Senior Vice President, Chief Accounting Officer (Age 57)
  • David W. Cragg, Senior Vice President - Human Resources (Age 61)
  • Bonnie A. Charpentier Ph.D., Senior Vice President - Regulatory Affairs and Compliance (Age 65)
  • Bradley Paul Morgan Ph.D., Senior Vice President - Research and Non-Clinical Development (Age 56)
  • Elisabeth Schnieders Ph.D., Senior Vice President - Business Development (Age 50)

Who owns Cytokinetics stock?

Cytokinetics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (10.10%), Wasatch Advisors Inc. (3.12%), Schwab Charles Investment Management Inc. (0.46%), Acadian Asset Management LLC (0.16%) and Fox Run Management L.L.C. (0.04%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.

Who sold Cytokinetics stock? Who is selling Cytokinetics stock?

Cytokinetics' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and Schwab Charles Investment Management Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Insider Buying and Selling for Cytokinetics.

Who bought Cytokinetics stock? Who is buying Cytokinetics stock?

Cytokinetics' stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc. and Fox Run Management L.L.C.. View Insider Buying and Selling for Cytokinetics.

How do I buy Cytokinetics stock?

Shares of Cytokinetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of Cytokinetics stock can currently be purchased for approximately $10.05.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $529.42 million and generates $106.41 million in revenue each year. The biopharmaceutical company earns $16.45 million in net income (profit) each year or ($1.66) on an earnings per share basis. Cytokinetics employs 127 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 E Grand Ave, SOUTH SAN FRANCISCO, CA 94080-4808, United States. The biopharmaceutical company can be reached via phone at +1-650-6243000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (CYTK)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  362 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  472
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cytokinetics (NASDAQ:CYTK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.902.903.003.11
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $18.20$17.90$22.30$21.11
Price Target Upside: 106.82% upside146.90% upside44.34% upside48.15% upside

Cytokinetics (NASDAQ:CYTK) Consensus Price Target History

Price Target History for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2018HC WainwrightSet Price TargetBuy$20.00HighView Rating Details
1/17/2018Cantor FitzgeraldReiterated RatingHold$10.00LowView Rating Details
11/29/2017Needham & Company LLCDowngradeStrong-Buy -> Buy$22.00 -> $12.00LowView Rating Details
11/22/2017Morgan StanleyReiterated RatingOverweight -> Overweight$25.00 -> $17.00N/AView Rating Details
11/21/2017JMP SecuritiesReiterated RatingOutperform$17.00 -> $13.00N/AView Rating Details
11/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$18.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$24.00N/AView Rating Details
8/4/2017CowenReiterated RatingBuy$19.00LowView Rating Details
3/23/2017Rodman & RenshawReiterated RatingBuy$25.00MediumView Rating Details
2/17/2017FBR & CoReiterated RatingOutperform$24.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$22.00N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$16.00 -> $14.00N/AView Rating Details
(Data available from 1/23/2016 forward)

Earnings

Cytokinetics (NASDAQ:CYTK) Earnings History and Estimates Chart

Earnings by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ CYTK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018($0.71)N/AView Earnings Details
10/26/2017Q3 2017($0.64)($0.60)$5.35 million$6.18 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.57)($0.60)$5.28 million$3.05 millionViewListenView Earnings Details
4/27/2017Q1 2017($0.11)($0.62)$5.08 million$4.15 millionViewN/AView Earnings Details
2/16/2017Q416($0.39)$0.16$14.10 million$33.14 millionViewListenView Earnings Details
10/27/2016Q3($0.27)$0.74$6.67 million$59.05 millionViewListenView Earnings Details
7/28/2016Q2($0.28)($0.29)$7.80 million$5.80 millionViewListenView Earnings Details
4/28/2016Q1($0.37)($0.31)$8.14 million$8.42 millionViewListenView Earnings Details
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details
7/29/2015Q2($0.28)($0.27)$4.00 million$6.54 millionViewListenView Earnings Details
4/30/2015Q1($0.08)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details
10/30/2014Q3($0.27)($0.16)$6.50 million$9.42 millionViewListenView Earnings Details
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details
10/30/2013Q3 2013($0.09)($0.43)$15.77 million$4.47 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.55)($0.58)$4.36 million$1.01 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.54)($0.54)$0.92 million$0.82 millionViewN/AView Earnings Details
2/5/2013Q4 2012($0.60)($0.42)ViewN/AView Earnings Details
10/30/2012Q3 2012($0.60)($0.42)ViewN/AView Earnings Details
7/31/2012Q2 2012($0.72)($0.78)ViewN/AView Earnings Details
4/26/2012Q1 2012($0.84)($0.78)ViewN/AView Earnings Details
2/2/2012Q4 2011($0.78)($0.88)ViewN/AView Earnings Details
10/27/2011Q3 2011($1.14)($0.88)ViewN/AView Earnings Details
7/28/2011Q2 2011($0.66)($1.39)ViewN/AView Earnings Details
4/27/2011Q1 2011($1.14)($1.08)ViewN/AView Earnings Details
2/14/2011Q4 2010($1.32)($1.01)ViewN/AView Earnings Details
10/28/2010Q3 2010($1.26)($1.15)ViewN/AView Earnings Details
7/28/2010Q2 2010($1.20)($1.19)ViewN/AView Earnings Details
4/29/2010Q1 2010($1.20)($1.18)ViewN/AView Earnings Details
2/3/2010Q4 2009($1.32)($1.20)ViewN/AView Earnings Details
10/28/2009Q3 2009($1.32)($0.82)ViewN/AView Earnings Details
7/29/2009Q2 2009$3.06$5.90ViewN/AView Earnings Details
4/30/2009Q1 2009($1.20)($1.24)ViewN/AView Earnings Details
2/10/2009Q4 2008($2.28)($1.31)ViewN/AView Earnings Details
10/30/2008Q3 2008($2.16)($1.67)ViewN/AView Earnings Details
7/31/2008Q2 2008($2.04)($1.87)ViewN/AView Earnings Details
4/29/2008Q1 2008($1.92)($1.69)ViewN/AView Earnings Details
1/31/2008Q4 2007($2.52)($1.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cytokinetics (NASDAQ:CYTK) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.4 EPS
Next Year EPS Consensus Estimate: $-1.87 EPS

Dividends

Dividend History for Cytokinetics (NASDAQ:CYTK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cytokinetics (NASDAQ CYTK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.20%
Institutional Ownership Percentage: 75.25%
Insider Trades by Quarter for Cytokinetics (NASDAQ:CYTK)
Insider Trades by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ CYTK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2018Caryn Gordon McdowellInsiderSell2,709$9.00$24,381.0015,077View SEC Filing  
11/2/2017Caryn Gordon McdowellInsiderSell4,260$12.94$55,124.4017,982View SEC Filing  
11/1/2017Fady Ibraham MalikEVPSell7,321$13.39$98,028.1947,540View SEC Filing  
11/1/2017Robert I BlumCEOSell5,000$13.51$67,550.0070,180View SEC Filing  
10/6/2017Caryn Gordon McdowellInsiderSell13,181$15.49$204,173.69View SEC Filing  
10/2/2017Robert I BlumCEOSell5,000$14.59$72,950.00View SEC Filing  
9/6/2017Caryn Gordon McdowellInsiderSell10,131$14.60$147,912.6019,801View SEC Filing  
9/1/2017Robert I BlumCEOSell5,000$14.71$73,550.0079,785View SEC Filing  
8/31/2017Bradley Paul MorganSVPSell118,330$15.00$1,774,950.0063,107View SEC Filing  
8/31/2017Santo J CostaDirectorSell5,000$15.00$75,000.005,000View SEC Filing  
8/29/2017Santo J CostaDirectorSell5,000$14.00$70,000.005,000View SEC Filing  
8/8/2017Caryn Gordon McdowellInsiderSell11,348$12.47$141,509.5621,570View SEC Filing  
8/1/2017Robert I BlumCEOSell5,000$13.79$68,950.0084,785View SEC Filing  
7/3/2017Robert I BlumCEOSell5,000$12.14$60,700.0088,385View SEC Filing  
6/1/2017Robert I BlumCEOSell5,000$13.62$68,100.0094,785View SEC Filing  
12/29/2016Fady Ibraham MalikEVPSell5,633$12.36$69,623.883,361View SEC Filing  
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.0030,000View SEC Filing  
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.0030,000View SEC Filing  
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.5010,000View SEC Filing  
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.002,883,845View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cytokinetics (NASDAQ CYTK) News Headlines

Source:
DateHeadline
Cytokinetics (CYTK) Given a $20.00 Price Target by HC Wainwright AnalystsCytokinetics (CYTK) Given a $20.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - January 20 at 7:38 PM
Cytokinetics (CYTK) PT Raised to $20 at HC Wainwright; The Year of CK-107 - StreetInsider.comCytokinetics (CYTK) PT Raised to $20 at HC Wainwright; 'The Year of CK-107' - StreetInsider.com
www.streetinsider.com - January 20 at 3:16 PM
Cytokinetics, Inc. (CYTK) Insider Caryn Gordon Mcdowell Sells 2,709 SharesCytokinetics, Inc. (CYTK) Insider Caryn Gordon Mcdowell Sells 2,709 Shares
www.americanbankingnews.com - January 18 at 9:58 PM
Cantor Fitzgerald Reaffirms "Hold" Rating for Cytokinetics (CYTK)Cantor Fitzgerald Reaffirms "Hold" Rating for Cytokinetics (CYTK)
www.americanbankingnews.com - January 18 at 1:50 PM
Zacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) Will Post Quarterly Sales of $4.83 MillionZacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) Will Post Quarterly Sales of $4.83 Million
www.americanbankingnews.com - January 13 at 5:00 AM
Zacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) to Announce -$0.71 EPSZacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) to Announce -$0.71 EPS
www.americanbankingnews.com - January 11 at 7:32 PM
BRIEF-Cytokinetics Announces Progress Against Vision 2020BRIEF-Cytokinetics Announces Progress Against Vision 2020
www.reuters.com - January 3 at 8:50 AM
Cytokinetics Announces Progress Against Vision 2020Cytokinetics Announces Progress Against Vision 2020
finance.yahoo.com - January 3 at 8:50 AM
Cytokinetics, Inc. (CYTK) Receives Consensus Recommendation of "Buy" from AnalystsCytokinetics, Inc. (CYTK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 2 at 1:42 PM
$4.83 Million in Sales Expected for Cytokinetics, Inc. (CYTK) This Quarter$4.83 Million in Sales Expected for Cytokinetics, Inc. (CYTK) This Quarter
www.americanbankingnews.com - December 28 at 8:32 PM
Cytokinetics, Inc. (CYTK) Expected to Post Earnings of -$0.71 Per ShareCytokinetics, Inc. (CYTK) Expected to Post Earnings of -$0.71 Per Share
www.americanbankingnews.com - December 26 at 7:20 AM
Contrasting Cytokinetics (CYTK) and Its PeersContrasting Cytokinetics (CYTK) and Its Peers
www.americanbankingnews.com - December 12 at 7:34 PM
Cytokinetics further discusses tirasemtiv results; down 2.5% - Seeking AlphaCytokinetics further discusses tirasemtiv results; down 2.5% - Seeking Alpha
seekingalpha.com - December 12 at 5:36 PM
5 Stocks To Watch For December 11, 2017 - Benzinga5 Stocks To Watch For December 11, 2017 - Benzinga
www.benzinga.com - December 11 at 5:22 PM
Cytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 MillionCytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 Million
www.americanbankingnews.com - December 10 at 6:36 AM
Cytokinetics (CYTK) & The Competition Financial SurveyCytokinetics (CYTK) & The Competition Financial Survey
www.americanbankingnews.com - December 8 at 5:14 PM
Cytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MNDCytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MND
finance.yahoo.com - December 8 at 5:04 PM
Cytokinetics, Inc. (CYTK) Receives Average Rating of "Buy" from BrokeragesCytokinetics, Inc. (CYTK) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 8 at 3:52 PM
-$0.71 Earnings Per Share Expected for Cytokinetics, Inc. (CYTK) This Quarter-$0.71 Earnings Per Share Expected for Cytokinetics, Inc. (CYTK) This Quarter
www.americanbankingnews.com - December 8 at 3:30 PM
Contrasting Cytokinetics (CYTK) & The CompetitionContrasting Cytokinetics (CYTK) & The Competition
www.americanbankingnews.com - December 7 at 9:24 AM
Cytokinetics (CYTK) Says New Publication Shows Respiratory Decline Correlated With Disease Progression in People ... - StreetInsider.comCytokinetics (CYTK) Says New Publication Shows Respiratory Decline Correlated With Disease Progression in People ... - StreetInsider.com
www.streetinsider.com - December 1 at 5:01 PM
Cytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MNDCytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MND
finance.yahoo.com - December 1 at 5:01 PM
New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve ActivationNew Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve Activation
finance.yahoo.com - November 30 at 5:07 PM
Cytokinetics (CYTK) Announces New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability ... - StreetInsider.comCytokinetics (CYTK) Announces New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability ... - StreetInsider.com
www.streetinsider.com - November 30 at 10:09 AM
Needham & Company LLC Downgrades Cytokinetics (CYTK) to BuyNeedham & Company LLC Downgrades Cytokinetics (CYTK) to Buy
www.americanbankingnews.com - November 29 at 8:44 AM
ETFs with exposure to Cytokinetics, Inc. : November 27, 2017ETFs with exposure to Cytokinetics, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 6:06 PM
Cytokinetics, Incorporated (CYTK) Downgraded by Cantor Fitzgerald to "Neutral"Cytokinetics, Incorporated (CYTK) Downgraded by Cantor Fitzgerald to "Neutral"
www.americanbankingnews.com - November 22 at 12:56 PM
Reviewing Cytokinetics, (CYTK) and AveXis (AVXS)Reviewing Cytokinetics, (CYTK) and AveXis (AVXS)
www.americanbankingnews.com - November 22 at 11:30 AM
Cytokinetics, Incorporated (CYTK) Receives "Overweight" Rating from Morgan StanleyCytokinetics, Incorporated (CYTK) Receives "Overweight" Rating from Morgan Stanley
www.americanbankingnews.com - November 22 at 8:52 AM
Cytokinetics, Incorporated (CYTK) Expected to Announce Quarterly Sales of $4.83 MillionCytokinetics, Incorporated (CYTK) Expected to Announce Quarterly Sales of $4.83 Million
www.americanbankingnews.com - November 22 at 4:02 AM
Cytokinetics, Incorporated (CYTK) Stock Rating Lowered by ValuEngineCytokinetics, Incorporated (CYTK) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - November 22 at 12:20 AM
OSUR Turns Heads, MRSN To Report Data By Year-end, CYTK Loses VitalityOSUR Turns Heads, MRSN To Report Data By Year-end, CYTK Loses Vitality
www.nasdaq.com - November 21 at 11:00 PM
Swinging at Lou Gehrigs disease, Peninsula drug maker strikes outSwinging at Lou Gehrig's disease, Peninsula drug maker strikes out
www.bizjournals.com - November 21 at 6:00 PM
Interesting CYTK Put And Call Options For January 2018Interesting CYTK Put And Call Options For January 2018
www.thestreet.com - November 21 at 5:59 PM
Cytokinetics neuro-degenerative drug fails late-stage trialCytokinetics' neuro-degenerative drug fails late-stage trial
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics shares drop 31% on late-stage ALS drug failureCytokinetics shares drop 31% on late-stage ALS drug failure
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics, Inc. (CYTK) Stock Gets Whacked on Disappointing Clinical Results in ALSCytokinetics, Inc. (CYTK) Stock Gets Whacked on Disappointing Clinical Results in ALS
finance.yahoo.com - November 21 at 5:59 PM
Why Is Cytokinetics Plunging Today?Why Is Cytokinetics Plunging Today?
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics, Incorporated: Buy the Dip or Pump the Brakes?Cytokinetics, Incorporated: Buy the Dip or Pump the Brakes?
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics Crumbles on Late-Stage ResultsCytokinetics Crumbles on Late-Stage Results
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics CEO: Optimism still there despite ALS drug s...Cytokinetics CEO: Optimism still there despite ALS drug s...
finance.yahoo.com - November 21 at 5:59 PM
Cytokinetics, Incorporated (CYTK) Earns Outperform Rating from JMP SecuritiesCytokinetics, Incorporated (CYTK) Earns Outperform Rating from JMP Securities
www.americanbankingnews.com - November 21 at 3:24 PM
Needham & Company LLC Downgrades Cytokinetics, Incorporated (CYTK) to BuyNeedham & Company LLC Downgrades Cytokinetics, Incorporated (CYTK) to Buy
www.americanbankingnews.com - November 21 at 3:24 PM
Cytokinetics,s (CYTK) "Overweight" Rating Reiterated at Piper Jaffray CompaniesCytokinetics,'s (CYTK) "Overweight" Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - November 21 at 3:24 PM
Cytokinetics, Incorporated (CYTK) Price Target Cut to $17.00Cytokinetics, Incorporated (CYTK) Price Target Cut to $17.00
www.americanbankingnews.com - November 21 at 12:00 PM
Cytokinetics, Target of Unusually High Options Trading (CYTK)Cytokinetics, Target of Unusually High Options Trading (CYTK)
www.americanbankingnews.com - November 18 at 2:02 AM
Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock? - Yahoo FinanceIs the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock? - Yahoo Finance
finance.yahoo.com - November 17 at 11:39 PM
Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock?Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock?
finance.yahoo.com - November 17 at 1:35 PM
Noteworthy Tuesday Option Activity: CYTK, RH, GNENoteworthy Tuesday Option Activity: CYTK, RH, GNE
www.thestreet.com - November 14 at 11:10 PM
Cytokinetics (CYTK) Announces Additional Results From COSMIC ... - StreetInsider.comCytokinetics (CYTK) Announces Additional Results From COSMIC ... - StreetInsider.com
www.streetinsider.com - November 14 at 6:09 PM

SEC Filings

Cytokinetics (NASDAQ:CYTK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cytokinetics (NASDAQ:CYTK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cytokinetics (NASDAQ CYTK) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.